The RheumNow Week in Review - 16 March 2018

Save

Dr. Jack Cush reviews the highlights from the news, journals and major meetings. Bigtime rheumatologic lessons with tales from intestinal crypts, the friendly skies & the hips of hockey players. Also the microbiome and lupus, benefits of ENT findings with GPA and rare risk of opportunistic infections with biologics.

FDA Panel Votes to Favor High Dose Xeljanz in Ulcerative Colitis

Save

Yesterday a FDA advisory panel voted 15-0 in favor of approving Xeljanz (tofacitinib) 10 mg bid for patients with moderate to severe ulcerative colitis.

The RheumNow Week in Review - 23 February 2018

Save

Dr Jack Cush reviews highlights from the past week on RheumNow.com. This week’s video is in two parts; for part Ii, go to https://buff.ly/2BM9MjL

Equal Cardiovascular Risks in Hypertensive Patients Treated with Selective and Nonselective NSAIDS

Save

A Taiwanese study of 55,629 hypertensive patients shows no increased risk of  major cardiovascular events comparing outcomes of patients started on COX-2 selective NSAIDs compared with nonselective NSAIDs (including ibuprofen, diclofenac and naproxen).

Abatacept Improves GvHD Outcomes

Save

The results from a phase 2 clinical trial presented at the American Society of Hematology meeting demonstrated that the drug abatacept was highly effective in managing severe acute graft-versus-host disease (GvHD) in patients receiving hematopoietic stem cell transplants.

RWCS Day 4 Podcast

Save

Listen in on the proceedings from the 2018 RWCS meeting in Maui, with excerpts from leading teachers in rheumatology. This podcast features presentations from Drs.

RWCS Meeting Begins Today

Save

The 11th annual meeting of the Rheumatology Winter Clinical Symposium (RWCS) begins today (2/7) and runs through Saturday (2/10) and features a premiere faculty delivering state-of-the-art lectures.

Problems with Biologic Drug Storage

Save

Is your patient’s refrigerator the problem with the inefficacy of biologic therapies? Studies show most patients don't store their biologics correctly, which may be a source of limited drug efficacy.

Salt Drives Gut-Brain Connection via IL-17

Save

A study from Nature Neuroscience shows that a high salt diet may mediate neurovascular disease by altering microbiome and the expansion of TH17 cells in the small intestine, thereby increasing plasma interleukin-17 (IL-17) and its subsequent effects on endothelium in the brain.

The RheumNow Week in Review - 8 December 2017

Save

Dr. Jack Cush covers the news and journal articles published on RheumNow.comin the past week.

ACR17 Good News – Ankylosing Spondylitis and Spondyloarthritis

Save

The following is a collection of AS/SpA-specific mentions culled from RheumNow's coverage of the Annual ACR 2017 meeting in San Diego.

The RheumNow Week in Review - 17 November 2017

Save

Dr. Jack Cush reviews the news and highlights from the past week on RheumNow.com. This week he covers FDA warnings on gout drugs, steroid use in Australia, biosimilars lost savings and methotrexate hepatotoxicity in psoriatic arthritis (PsA).

Thiopurines and Anti-TNF drugs in IBD Associated with Increased Lymphoma Risk

Save

JAMA presents a French report on the cancer risk of thiopurine or tumor necrosis factor inhibitor (TNFi) use in adult patients with inflammatory bowel disease (IBD) and finds a raised risk for lymphoma in IBD compared to those not treated with these agents.  (Citation source 

MTX Doubles Hepatotoxicity Risk in Psoriasis Patients

Save

A study from the University of Pennsylvania Perelman School of Medicine was published in the Journal of Investigative Dermatology showing that the risk of incident liver disease doubled when patients with psoriasis (PsO) or psoriatic arthritis (PsA) take methotrexate (MTX), but not when

Gut-derived TNF: Connection Between Crohn’s and SpA and Sacroiliitis

Save

The pathogenesis between microscopic gut inflammation leading to the development of Crohn’s disease and sacroiliitis has been poorly understood. Dr. Debusschere, et al sought to understand this important link between IBD and axial SpA.

CALM Study: Tight Control with Anti-TNF Wins in Crohn's Disease

Save

Not unlike rheumatoid arthritis and other inflammatory disorders, therapeutic efficacy in Crohn's disease (CD) is often assessed clinically. There is growing use and interest in biomarkers of intestinal inflammation, such as faecal calprotectin and C-reactive protein.

Biosimilars Projected to Yield $54 Billion in Savings

Save

A primary projected advantage to biosimilar drugs development has been cost savings. A new study from the RAND Corporation suggests biosimilars could cut health care spending in the United States by $54 billion over the next decade. This number is nearly 20 percent greater than a similar study conducted three years ago by the same researchers. 

Stelara FDA Approved for Use in Adolescent Psoriasis

Save

Johnson & Johnson has announced that they have received an expanded FDA approval for the use of ustekinumab (Stelara) in treating adolescent patients, aged 12 and over, with moderate to severe plaque psoriais.

IBD Associated with Increased risk of Autoimmune and Inflammatory Diseases

Save

A registry based study has shown higher rates of immune mediated diseases (IMD) in patients with inflammatory bowel disease (IBD).

Safety of Long-Term PPI Use

Save

The current issue of JAMA reviews the safety of long-term use of proton pump inhibitors (PPI). The following is a collection of the evidence about these purported risks.

Fractures